Sign up USA
Proactive Investors - Run By Investors For Investors

Pfizer tops Q4 hopes but lowers guidance for 2016

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.
Pfizer tops Q4 hopes but lowers guidance for 2016
Pfizer is merging with Allergan

--- adds share price---

Pharma giant Pfizer (NYSE:PFE) beat expectations in its fourth quarter but tempered forecasts for the coming year.

The firm reported on Tuesday that fourth-quarter earnings halved compared to the previous year to US$61mln, or 10 cents per share (EPS), from US$1.22bn, or 19 cents per share.

However, the results include three months of legacy Hospira global operations, Pfizer said, and adjusted EPS was 53 cents per share, slightly ahead of hopes.

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.

But for, 2016, the company said it expects "significant negative currency impact related to Venezuela."

Excluding the effects of its merger with Allergan, Pfizer said it expects adjusted EPS of US$2.20 to US$2.30, including the impact of currency headwinds, below estimates of US$2.38 per share.

Before the resumption of trading on Wall Street, shares were trading 1.7% lower in the pre-market trading, before nudging 0.77% higher in the regular session at US$30.21.

View full PFE profile View Profile

Pfizer Timeline

Related Articles

April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
mri scanner
January 31 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntingdon’s and multiple sclerosis

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use